Device used to treat Ebola patient; Harvard to focus on devices and diagnostics;

@FierceMedDev: Who are today's leading women in med tech? Check out our top women in medical devices list to find out. Special report | Follow @FierceMedDev

@VarunSaxena2: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: $COV recalled some defibrillator electrodes made by $PHG. Story from MassDevice | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story | Follow @MichaelGFierce

> For the first time, Aethlon Medical used its Hemopurifier therapy on a patient infected with the Ebola virus. Release

> Harvard's Medical and Business schools put developing news device and diagnostics at the top of its list of the Deans' Health & Life Sciences Challenge. More

> Viewics, a CA-based startup, received $8 million in a funding round led by Canvas Venture Fund to use toward controlling hospitals' lab test costs. Story

Biotech News

@FierceBiotech: Meet some of the revolutionaries in biotech R&D. Report | Follow @FierceBiotech

@JohnCFierce: AbbVie to Shire: Maybe we should reconsider that $54B merger deal after all - $SHPG down 27%. Article | Follow @JohnCFierce

@DamianFierce: Fantastically timed press release: "Shire Announces the Organize Your Stuff Contest Winners." Release | Follow @DamianFierce

@EmilyMFierce: These 10 drugs could stop Ebola. Feature | Follow @EmilyMFierce

> Selecta banks $20M for trial work, inks a pact with Sanofi on diabetes. Story

> Forward Pharma pulls off a $221M IPO with eyes on unseating Biogen. More

> DNAtrix pockets $20M to get its cancer-fighting virus into Phase III. Article

Pharma News

@FiercePharma: Our newest special report is live! The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: Novartis says construction delay of Russian plant no big deal, technical changes and not tied to sanctions. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi wins kudos for airing bribery probe. Phase II? Take to social media. Article | Follow @CarlyHFierce

> FDA grants a combo-med exclusivity wish. Why is that a problem? Story

> Former finance analyst charged in insider trading case. News

> AbbVie-Shire deal in jeopardy, but not necessarily dead. More

Drug Delivery News

> Robert Langer talks science, business and how they intersect. More

> Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story

> Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. Report

> Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients. Item

> Intersect ENT says latest data on dissolving implants for chronic sinusitis are encouraging. Article

Diagnostics News

> Gene sequencing helps Northwestern team diagnose one cause of epilepsy. More

> Exact Sciences nails coveted Medicare coverage for colon cancer DNA test. News

> SomaLogic, CO hospital to develop biomarkers/Dx tests for childhood diseases. Story

> British startup finishes quick and easy Ebola test. Report

> Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. Article

Pharma Marketing News

> Teva's SCOTUS appeal is here. But how much can the outcome really affect Copaxone's market share? More

> World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Read

> Looking 'beyond the pill'? Start with an app--and then follow this to-do list. Story

> Can Amgen's marketing muscle vault its Humira biosim ahead of rivals? More

> Pictures tell the story in AstraZeneca's breast cancer photo-sharing push. Article

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.